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The regulation of phosphatase activity is fundamental to the control of intracellular signalling
and in particular the tyrosine kinase-mediated mitogen-activated protein kinase (MAPK)
pathway. Shp2 is a ubiquitously expressed protein tyrosine phosphatase and its kinase-
induced hyperactivity is associated with many cancer types. In non-stimulated cells we find
that binding of the adaptor protein Grb2, in its monomeric state, initiates Shp2 activity
independent of phosphatase phosphorylation. Grb2 forms a bidentate interaction with both
the N-terminal SH2 and the catalytic domains of Shp2, releasing the phosphatase from its
auto-inhibited conformation. Grb2 typically exists as a dimer in the cytoplasm. However, its
monomeric state prevails under basal conditions when it is expressed at low concentration, or
when it is constitutively phosphorylated on a specific tyrosine residue (Y160). Thus, Grb2 can
activate Shp2 and downstream signal transduction, in the absence of extracellular growth
factor stimulation or kinase-activating mutations, in response to defined cellular conditions.
Therefore, direct binding of Grb2 activates Shp2 phosphatase in the absence of receptor
tyrosine kinase up-regulation.
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The reciprocal process of phosphorylation by kinases, anddephosphorylation by phosphatases, of selected residuesregulates the intensity and longevity of intracellular tyr-
osine kinase-mediated signal transduction. The SH2 domain-
containing tyrosine phosphatase 2, Shp2, (aka. PTPN11) plays a
prominent role in this process in a multitude of receptor tyrosine
kinase (RTK)-mediated signalling pathways, including activation
of the extracellular signal-regulated kinase Erk1/2 (aka. mitogen-
activated protein kinase, MAPK) pathway1–5. Shp2 is ubiqui-
tously expressed in vertebrate cells and consists largely of, in
sequential order: two Src homology 2 (SH2) domains (NSH2 and
CSH2, respectively); a protein tyrosine phosphatase (PTP)
domain; and a C-terminal tail with two tyrosyl phosphorylation
sites (Y542 and Y580) and a proline-rich sequence (residues
559PLPPCTPTPP568).
Shp2 was the first phosphatase to be identified as a human
oncoprotein6,7, and a large body of experimental and clinical
studies has indicated that the hyperactivation of Shp2 contributes
to tumour progression in, for example, breast cancer8–11. A great
deal of interest has been shown in anticancer therapeutic
approaches involving downregulation of Shp212–15. However,
despite extensive investigation, a lack of a mechanistic under-
standing of its upregulation in solid cancers has hindered phar-
maceutical development. Existing inhibitors targeting phosphatase
activity show low selectivity because of the highly conserved
amino-acid sequences of phosphatase domains. However, more
recently an approach based on small molecule stabilisation of the
auto-inhibited conformation of Shp2 has shown efficacy16.
Crystal structural detail revealed that Shp2 utilises an auto-
inhibitory mechanism that prevails under basal conditions17.
NSH2 forms an intramolecular interaction with the PTP domain,
directly blocking access to the catalytic site, resulting in a ‘closed’
state. In this state, the NSH2 domain adopts a conformation that
contorts its phosphopeptide binding cleft. Gain-of-function
somatic mutations that result in the abrogation of the interac-
tion between NSH2 and the PTP domain have been shown to be
activating7,18. Auto-inhibition is released through one of two
mechanisms involving the SH2 domains of Shp2. In the first, both
N- and CSH2 interact with a binding partner including a phos-
phorylated bisphosphoryl tyrosine-based activation motif19–23.
The second, more controversial, mechanism occurs under con-
ditions where Shp2 has been phosphorylated, typically by an
RTK1,24,25. This induces an intramolecular, bidentate interaction
between the two phosphorylated tyrosine residues in the C-
terminus of Shp2 and both NSH2 and CSH224,26,27.
We have previously investigated the constitutive control that
the adaptor protein growth factor receptor-bound protein 2,
Grb2, exerts over Shp2 in non-stimulated cells28,29. Grb2 consists
of an SH2 domain sandwiched between two SH3 domains and is
integral to several RTK-mediated signalling pathways. Non-
phosphorylated Grb2 exists in a concentration-dependent dimer-
monomer equilibrium (Kd= 0.8 µM)29. Depletion of intracellular
expression of Grb2 results in increased concentrations of
monomer30. In addition, monomeric Grb2 (mGrb2) will also
prevail when it is phosphorylated on tyrosine 160 (Y160) in the
dimer interface. Under basal conditions, in the absence of growth
factor stimulation, Grb2 cycles between the phosphorylated
mGrb2, and the non-phosphorylated, typically dimeric state. The
former is dependent on constitutive, background RTK activity,
e.g., from fibroblast growth factor receptor 2 (FGFR2), whereas
the latter results from concomitant Shp2 activity30.
In this work, we provide molecular mechanistic detail on the
activation of Shp2 in the absence of the two phosphorylation-
dependent mechanisms highlighted above. Using the monomeric
phosphorylation charge mimetic Grb2 mutant Y160E (Grb2Y160E)30,
we show that in non-stimulated cells Grb2Y160E is able to greatly
enhance Shp2 phosphatase activity via a bidentate interaction
involving two discrete interfaces; (1) between the NSH2 domain of
Shp2 and the SH2 of Grb2, and (2) between the PTP domain of Shp2
and the CSH3 of Grb2. The binding of Grb2Y160E releases Shp2 from
its auto-inhibited state and results in an increase in the phosphatase
activity independent of kinase-induced stimulation.
RTK-mediated signal transduction in cells that are not exposed
to activating concentrations of extracellular stimuli is funda-
mental in maintaining homoeostasis and metabolic regulation.
Aberrancies in this form of signalling can evoke cancer
outcomes31–33. However, our appreciation of this form of sig-
nalling remains limited. This work provides a valuable example of
how in the absence of growth factor stimulation a key enzyme can
be upregulated and control MAPK pathway response.
Results
Shp2 interacts with monomeric Grb2 in the absence of growth
factor. Mutation of Y160 to glutamate (a phosphotyrosine charge
mimetic) in the Grb2 dimer interface abrogates self-association of
the adaptor protein30,32. To characterise the interaction between
full-length Shp2 (Shp2WT) and monomeric Grb2 (including
Y160E mutation, Grb2Y160E25) we initially used microscale ther-
mophoresis (MST) to measure the affinity of the interaction of
full-length proteins (Kd= 0.33 ± 0.04 µM; Fig. 1a, Table 1 and
Supplementary Data 1). We demonstrated that Grb2Y160E can
bind at two discrete sites on Shp2 using biolayer interferometry
(BLI) on the following four GST-tagged phosphatase constructs:
Shp2WT, the tandem SH2 domains (residues 1–220: Shp22SH2),
the PTP domain (251–524: Shp2PTP) and a peptide corresponding
to the C-terminal 69 amino acids (525–593: Shp2C69). Both
Shp2WT as well as Shp22SH2 polypeptides were able to interact
with Grb2Y160E. The truncated Shp2PTP bound to Grb2Y160E
weakly, whereas the C-terminal tail failed to interact (Fig. 1b and
Supplementary Data 1). These two binding sites were confirmed
in an in vitro pull-down experiment in which Grb2Y160E was
precipitated by both GST-Shp22SH2 and GST-Shp2PTP (Fig. 1c,
Supplementary Fig. 4a and Supplementary Data 1). The interac-
tion with GST-Shp2PTP was less pronounced. Interaction between
Grb2WT and the Shp2 constructs appears to be negligible sug-
gesting that, under the experimental conditions, the prevailing
dimeric Grb2 is unable to interact. The limited complex forma-
tion seen with extended exposure of the blot is again presumed to
be with the low population of monomeric protein at equilibrium
(Fig. 1c inset, Supplementary Fig. 4a and Supplementary Data 1).
Upon phosphorylation, tyrosines 542 and 580 on the C-terminal
tail of Shp2 are known binding sites for Grb2 SH2 domains34. To
confirm our in vitro observation in a cellular context, we measured
intracellular binding of Shp2Δ69 (deleted of 69 residues 525–593 to
eliminate SH2-phosphotyrosine mediated interactions) to Grb2Y160E.
We used fluorescence lifetime imaging microscopy (FLIM) to detect
stable complexes through fluorescence resonance energy transfer
(FRET) between fluorophore-tagged proteins transfected into
HEK293T cells under serum-starved conditions. FRET was
confirmed by the left-shift of the fluorescence lifetime from the
control lifetime measurements of donor (CFP-Grb2) in the presence
of non-specific RFP-alone acceptor (2.2 nsec; Fig. 1d). No interaction
between CFP-Grb2WT and RFP-Shp2Δ69 was observed since the
fluorescent lifetime remains largely unaffected. Grb2WT exists in a
monomer-dimer equilibrium and CFP-Grb2WT overexpression
would favour dimer at the elevated adaptor protein concentration,
hence limiting the availability of Grb2 to interact with Shp2Δ69. To
circumvent concentration-dependent dimerisation, we used the
monomeric CFP-Grb2Y160E in the FLIM-binding assay. FRET
between CFP-Grb2Y160E and Shp2Δ69 shows a left-shifted fluores-
cence lifetime by 100 psec shorter than the RFP-alone control or
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CFP-Grb2WT (Fig. 1d lower panel). This clearly demonstrates that
only the monomeric Grb2Y160E interacts with Shp2. Immunopreci-
pitation further revealed that Grb2Y160E constitutively associates with
Shp2WT in the absence of ligand stimulation (Supplementary Fig. 1).
To further confirm the bidentate interaction in a cellular context, we
co-expressed CFP-Grb2Y160E with RFP-Shp22SH2, RFP-Shp2PTP, or
RFP alone in HEK293T cells. RFP-Trap immunoprecipitation
demonstrates that both RFP-Shp22SH2 and RFP-Shp2PTP can
precipitate CFP-Grb2Y160E (Fig. 1e, Supplementary Fig. 4b and
Supplementary Data 1). Again, the interaction with GST-Shp2PTP
was less pronounced. This result is consistent with our in vitro data
shown in Figs. 1b and 1c.
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The SH2 domain of Grb2 binds to the N-terminal SH2 domain
of Shp2. The affinity of Shp22SH2 binding to monomeric Grb2Y160E
was determined by MST (Kd= 0.28 ± 0.03 µM; Fig. 2a, Table 1 and
Supplementary Data 2). The possibility of binding of the pY-
mimetic glutamate of Grb2Y160E to either of the SH2 domains of
Shp22SH2 was ruled out because on mutating arginine residues
normally required for pY binding in the respective SH2 domains
of both proteins (on Shp2, R32A/R138A; Shp22SH2 R32A/R138A and
on Grb2 R86A; Grb2R86A/Y160E), Grb2R86A/Y160E was still capable of
binding to Shp22SH2 R32A/R138A with similar affinity to the wild-type
Shp22SH2 construct (Kd= 0.15 ± 0.01 µM; Fig. 2b, Table 1 and
Supplementary Data 2). Having observed the Shp22SH2 interaction
with Grb2, we sought to identify whether an individual domain was
responsible for critical contact. GST-tagged Shp22SH2 R32A/R138A, as
well as the individual SH2 domains (N-terminal SH2 domain:
Shp2NSH2 and C-terminal SH2 domain: Shp2CSH2), were used in
pull-down experiments in which the NSH2, and not the CSH2,
domain of Shp2 was shown to be sufficient for Grb2 binding
(Fig. 2c, Supplementary Fig. 4c and Supplementary Data 2). Re-
probing the blot with an anti-pY antibody revealed that the inter-
action was not mediated through phosphorylated tyrosine(s) or
glutamate on Grb2Y160E. This was further confirmed through
in vitro binding assays using two phosphopeptides corresponding to
the phosphorylatable tyrosine residues on Grb2 (pY160 and
pY209), which show negligible interaction with Shp22SH2. (Sup-
plementary Fig. 2a and Supplementary Data 5). Our data, therefore
are consistent with a non-canonical, phosphorylation-independent
interaction between Shp22SH2 and Grb2Y160E.
Having established the role of Shp2NSH2 in binding to unpho-
sphorylated Grb2Y160E, we attempted to establish which domain(s)
of Grb2 was required for recognition of the phosphatase. GST-
tagged Shp2NSH2 was captured on a GST BLI sensor and was
exposed to the isolated SH2, as well as NSH3 and CSH3 domains
of Grb2 (Grb2SH2, Grb2NSH3 and Grb2CSH3, respectively). The data
indicate that Grb2SH2 binds to Shp2NSH2 (Supplementary Fig. 2b),
accompanied by a weaker interaction with Grb2CSH3. MST
experiments on the same isolated domains of Grb2 binding to
Shp2NSH2 confirmed that the interaction with Grb2SH2 was
dominant (Kd= 33.8 ± 4.5 µM). Interactions with both the SH3
domains of Grb2 were substantially weaker (Grb2NSH3; Kd= 422 ±
21.5 µM and Grb2CSH3; Kd= 207 ± 16.8 µM (Fig. 2d, Table 1 and
Supplementary Data 2).
To assess the impact of the Grb2SH2 domain binding to Shp2-
NSH2 domain, we carried out NMR titration experiments based
on 2D (1H, 15N) HSQC spectra of 15N-Shp2-NSH2 domain in the
absence, and the presence of an increasing concentration of
unlabelled Grb2SH2 domain. Peak assignments of Shp2NSH2
backbone 1H-15N resonances were derived from a suite of
triple-resonance experiments (81% assignment coverage; Supple-
mentary Fig. 3). The addition of Grb2SH2 led to chemical shift
perturbations (CSPs) for several resonances, indicating disruption
of local chemical environments of specific amino acids as a result
of complex formation (Fig. 2e). Comparison of the spectra of the
free Shp2NSH2, and the Shp2NSH2-Grb2SH2 complex showed that
the average CSPs are relatively small. However, a limited number
of residues show pronounced changes (Fig. 2f). The CSPs
(>0.0075 ppm) were mapped onto a crystal structural representa-
tion of Shp2NSH2 (PDB code: 2SHP; Fig. 2g, h). From this, it is
possible to interpret a mechanism for Grb2SH2-domain binding.
The reported crystal structural data of Shp2 (PDB: 2SHP) reveal a
non-phosphorylated auto-inhibited structure in which NSH2
directly interacts with the PTP domain, blocking the access of
phosphorylated substrates. We see that a number of residues that
are not within the Shp2-NSH2-PTP interface are perturbed by
binding Grb2SH2 (T12, V25, Q57 and Y100; Fig. 2h) and are likely
to represent a discrete and extended interface formed between
Grb2 and Shp2. In addition to this, we observe that a subset of
residues that are within the intramolecular auto-inhibited inter-
face also show CSPs (G39, F41, G60, Y62 and K70; Fig. 2f, g). For
instance, G60 and Y62 are located on the DE loop, which inserts
into the PTP domain catalytic site interacting with residues of
the catalytic loop of Shp217. This suggests that binding of Grb2SH2
is also able to induce a distal conformational change in Shp2NSH2
capable of disrupting the auto-inhibited intramolecular interface
Fig. 1 Shp2 interacts with monomeric Grb2 in a phosphorylation-independent manner. a MST measurement of full-length Shp2 binding to fluorescent
labelled monomeric Grb2. Data are presented as (mean ± SD) of technical triplicates. For further details, see Table 1 and Methods. b BLI characterisation of
individual Shp2 domains binding to GST-Grb2Y160E immobilised on a GST sensor. GST-Grb2Y160E was captured and the sensor and 10 µM of each Shp2
protein was used to test the interaction. Black: Shp2WT, Red: Shp22SH2, Green: Shp2PTP, Blue: Shp2C69. The BLI sensorgram indicates that the Shp22SH2 and
Shp2PTP mediate the interaction with Grb2. c GST pull-down experiment using GST-tagged Shp22SH2 and GST-tagged Shp2PTP to precipitate monomeric or
dimeric Grb2 (Grb2Y160E or Grb2WT, respectively). The pull-down results clearly demonstrate the interaction of Shp2 with monomeric Grb2. The blot
represents three independent experiments. Inset: Densitometric analysis of GST pull-down results. Results are represented as mean ± SD. Statistics were
determined using an unpaired Student’s t test. d Fluorescence lifetime imaging microscopy (FLIM) displaying fluorescence resonance energy transfer
(FRET) between CFP-Grb2WT and RFP-alone control (top); CFP- Grb2WT and RFP- Shp2Δ69 (middle); Grb2Y160E and RFP-Shp2Δ69 (bottom). The lifetime-
image was generated using a false colour range pixel-by-pixel lifetime value corresponding to the average lifetime shown in the histograms. Two
independent experiments were performed and each time 5–10 cells were counted. e RFP-trap immunoprecipitation of Shp2 domain complexed with CFP-
Grb2Y160E. This demonstrated that both Shp22SH2 and Shp2PTP domains can form complexes with Grb2Y160E in HEK293T cells. The blot represents three
independent experiments. Inset: densitometric analysis of RFP-trap immunoprecipitation. Results are represented as mean ± SD. Statistics were determined
using a paired Student’s t test.
Table 1 Binding affinities (Kd, µM) obtained from this study
using MST.
Target protein Ligand Kd (µM)
Grb2Y160E Shp2WT 0.33 ± 0.04
Grb2Y160E Shp22SH2 0.28 ± 0.03
Grb2R86A/Y160E Shp22SH2 R32A/R138A 0.15 ± 0.01
Shp2NSH2 Grb2SH2 33.8 ± 4.5
Shp2NSH2 Grb2NSH3 422 ± 21.5
Shp2NSH2 Grb2CSH3 207 ± 16.8
Shp2PTP Grb2Y160E 0.30 ± 0.03
Grb2CSH3 VLHDGD297PNEP300VSDYIN N.B.
Grb2CSH3 TKCNNS322KPKK325SYIATQ 173 ± 6.89
Grb2CSH3 VERGKS366KCVK369YWPDEY 122 ± 7.24
Grb2CSH3 YGVMRV386RNVK389ESAAHD N.B.
Grb2CSH3 AHDYTL399RELKLSK405VGQ N.B.
Grb2CSH3 WPDHGV429PSDP432GGVLDF 18.1 ± 0.188
Target proteins were fluorescently labelled. Serial dilutions of ligands were titrated in order to
determine the binding affinity.
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releasing the ‘closed’ structure and hence activating the
phosphatase.
The CSH3 domain of Grb2 interacts with Shp2PTP. Data shown
in Figs. 1b and 1c revealed that, as well as binding to Shp22SH2,
Grb2Y160E also formed an interaction with Shp2PTP. We explored
this further using MST and found that the isolated Shp2PTP binds
Grb2Y160E with a similar affinity to the interaction with Shp22SH2
(Kd= 0.30 ± 0.03 µM; Fig. 3a, Table 1 and Supplementary
Data 3). To identify which domain of Grb2 interacts with
Shp2PTP we used GST-fused Grb2SH2, Grb2NSH3 and Grb2CSH3
constructs to precipitate recombinant Shp2PTP. The pull-down
indicated that only Grb2CSH3 can bind to the PTP domain
(Fig. 3b, Supplementary Fig. 4d and Supplementary Data 3). SH3
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domains recognise sequences usually incorporating the motif
PXXP (where X is any amino acid), although the atypical R/
KXXK motif has also been associated with SH3 domain recog-
nition. We found that there are two PXXP motifs (297PNEP300
and 429PSDP432) and four R/KXXK SH3 domain-binding motifs
(322KPKK325, 366KCVK369, 386RNVK389 and 399RELKLSK405)
within the PTP domain, which could potentially serve as
Grb2CSH3 binding sites. We, therefore, performed MST assays
using Grb2Y160E and six 16-residue peptides incorporating these
sequences. Binding data showed that the Grb2CSH3 had the
highest affinity for the 429PSDP432 on the Shp2PTP (Kd ~ 18 µM;
Fig. 3c, Table 1 and Supplementary Data 3). This interaction is
~60-fold weaker than the interaction between the intact PTP
domain and Grb2Y160E, suggesting that the peptides do not
entirely represent the full site of interaction.
As Grb2 binds to Shp2 through two apparently discrete
interactions largely represented by, (1) Grb2SH2 binding to
Shp2NSH2, and (2) Grb2CSH3 binding to Shp2PTP, we used
isothermal titration calorimetry (ITC) to qualitatively corroborate
these two binding events. The binding isotherm shows a biphasic
profile, resulting from an initial binding event with a stoichio-
metry of 2:1 Shp2Δ69:Grb2Y160E, which was succeeded by a second
binding event with a stoichiometry of unity as more Grb2Y160E
was titrated (Fig. 3d and Supplementary Data 3). These data can
be reconciled by a model in which in the initial injections
Grb2Y160E is saturated by excess Shp2Δ69. Under these conditions,
Shp2Δ69 will occupy both binding sites on Grb2 (i.e., Grb2SH2
binding to Shp2NSH2 on one Shp2Δ69 molecule, and Grb2CSH3
binding to Shp2PTP on another Shp2Δ69 molecule). On further
addition of Grb2Y160E, based on the final stoichiometry of 1:1, the
complex involves a bidentate interaction in which both the SH2
and CSH3 domain of a single Grb2 concomitantly bind to the
NSH2 and PTP domains of a single Shp2, respectively.
Grb2 increases activity independent of Shp2 phosphorylation.
The bidentate binding of Grb2, which includes an interaction
with both the NSH2 and the PTP domains of Shp2 implies that
complex formation could influence phosphatase activity. From
our accumulated data, we speculate that the binding of mono-
meric Grb2 promotes a conformational change releasing Shp2
from the auto-inhibited state. To investigate this, we tagged
Shp2Δ69 at both the N- and C-termini with blue fluorescent
protein (BFP) and green fluorescent protein (GFP), respectively.
When this pair of fluorophores are in close proximity (i.e., as
would be expected in the auto-inhibited state), excitation of BFP
results in fluorescence resonance energy transfer between the two
fluorophores, and hence a reduction in the emission intensity
from BFP with a concomitant increase from GFP. Conversely,
distancing the fluorophores through conformational change
reverses this outcome. Steady-state FRET was measured whilst
adding Grb2Y160E to Shp2Δ69 (Fig. 4a and Supplementary Data 4).
The data clearly show that, prior to Grb2 addition, the BFP donor
emission is low and GFP acceptor emission is high. Recovery of
FRET donor BFP emission and a decrease in FRET acceptor GFP
emission with increasing concentration of Grb2Y160E results in the
growing population of Grb2Y160E–Shp2Δ69 complex undergoing a
conformational change from the auto-inhibited state to a state
where the termini of Shp2Δ69 are separated.
To assess whether the Grb2 binding-induced conformational
change affected enzymatic activity, we conducted an in vitro
phosphatase assay. A pY-containing peptide substrate (END-
pYINASL) was incubated with non-phosphorylated Shp2Δ69 and
different concentrations of Grb2Y160E. Free phosphate generated
from hydrolysis of the pY was measured by the absorbance of a
malachite green molybdate phosphate complex (Fig. 4b and
Supplementary Data 4). A significant increase in phosphatase
activity was measured with the increasing presence of Grb2Y160E.
Importantly, a similar level of turnover of the peptide was
observed on comparing the monomeric Grb2-induced phospha-
tase activity to that observed for phosphorylated Shp2 in the
absence of the adaptor protein (pShp2; Fig. 4c and Supplementary
Data 4). These in vitro experiments suggest that under basal
conditions Shp2 activity can be upregulated through binding to
monomeric Grb2 alone, and that this activity is at least as high as
occurs when the phosphatase is phosphorylated as seen in growth
factor-stimulated cells.
Monomeric Grb2Y160E is associated with the upregulation of
Shp2 in cancer. Shp2 activity has been shown to play a key role in
cancer progression. As Grb2Y160E can promote phosphatase
activity in the absence of Shp2 phosphorylation, this could lead to
a proliferative outcome in cells through upregulation of the Erk1/
2 pathway without the need for the elevated kinase activity often
associated with cancer phenotypes. The role of upregulation of
non-phosphorylated Shp2 through binding to monomeric Grb2
in cancer has not previously been investigated. For example,
in the triple-negative breast cancer cell line MDA-MB-468 in
the absence of extracellular stimulation, we see negligible phos-
phorylated Shp2 (pShp2). However, there is a significant con-
centration of phosphorylated Erk1/2 (pErk1/2; Fig. 4d,
Supplementary Fig. 4e and Supplementary Data 4). These cells
have a background level of monomeric phosphorylated Grb2.
Indeed, Grb2 phosphorylation under basal non-stimulatory
conditions has been reported for a number of cell lines28
(Fig. 4d lower blot). These data are consistent with monomeric
Grb2 being able to upregulate MAPK signalling (as shown by
Fig. 2 Identification of binding domain on Grb2 and Shp22SH2 domains. a MST measurement of Shp22SH2 binding to fluorescent labelled Grb2Y160E. For
further details, see Table 1 and Methods. Data are presented as (mean ± SD) of technical triplicates. b MST measurement of Shp22SH2 R32A/R138A binding to
fluorescent labelled Grb2R86A/Y160E. This experiment confirms a phosphorylation-independent interaction. Data are presented as (mean ± SD) of technical
triplicates. c GST pull-down experiment using GST-tagged Shp2NSH2, Shp2CSH2, Shp22SH2 and its SH2 domain-deficient mutants. The pull-down results
indicate that SH2 domain-deficient mutants have no effect on precipitating Grb2 and identify that the NSH2 of Shp2 mediates the interaction with Grb2.
The blot represents three independent experiments. Inset: densitometric analysis of GST pull-down results. Results are represented as mean ± SD.
Statistics were determined using a paired Student’s t test. dMST characterisation of Grb2 individual domains binding to fluorescent labelled Shp2NSH2. The
result indicates that the SH2 domain of Grb2 predominately binding to Shp2NSH2. Data are presented as (mean ± SD) of technical replicates (SH2) or
triplicates (NSH3 and CSH3). e Interaction of 15N-labelled Shp2NSH2 and Grb2SH2 determined by NMR chemical shift perturbation (CSP) plot for the
interaction of Grb2SH2 to 15N-labelled Shp2NSH2. Minimal chemical shift perturbation upon Grb2SH2 mapped on Shp2NSH2 sequence. f Comparison of
Shp2NSH2 chemical shifts in the presence and absence of Grb2SH2. Overlay of a region of the 15N-1H HSQC (heteronuclear single-quantum coherence)
spectra of Shp2NSH2 and Grb2SH2 complex (red) and of Shp2NSH2 alone (black). gMapping on the Shp2-NSH2 domain of the (PDB: 2SHP) of the consensus
residues (painted light yellow to red) exhibiting strong CSPs upon Grb2SH2 binding. h Mapping on the surface of Shp2 (PDB: 2SHP) of the consensus
residues (painted light yellow to red) exhibiting strong CSPs upon Grb2SH2 binding. The Shp2NSH2 domain is in grey, Shp2CSH2 domain is in blue and the
SHp2PTP domain is in purple. This identifies the potential binding sites on Shp2NSH2 for Grb2SH2 binding.
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Fig. 3 Characterisation of Grb2Y160E binding to Shp2PTP domain. aMST measurement of Shp2PTP binding to fluorescent labelled Grb2Y160E (0.1 µM). Both
PTP domain and tandem 2SH2 domains show similar affinity to Grb2Y160E. Data are presented as (mean ± SD) of technical triplicates. b GST pull-down
experiment using GST-tagged individual Grb2 domain (NSH3, SH2 and CSH3) to precipitate Shp2 PTP domain. The result clearly indicates the interaction
is mediated through Grb2 CSH3 domain. The blot represents three independent experiments. Inset: densitometric analysis of GST pull-down results.
Results are represented as mean ± SD. Statistics were determined using an unpaired Student’s t test. c Sequence analysis identifies six potential PxxP or
R/KxxK (x is any amino residue) motifs for Grb2 CSH3 domain interaction. Synthesised peptides were used to test the interactions with Grb2 CSH3
domain (Atto 488 labelled, 0.1 µM) using MST. The results show 322KPKK325, 366KCVK369 and 429PSDP432 interact with Shp2 PTP domain.
Motif 429PSDP432 binds to Shp2 PTP domain with the highest affinity of 18 µM. See Table for detailed information and peptide sequences. Data are
presented as (mean ± SD) of technical replicates (peptide 322–325 and peptide 429–432) or triplicates. d ITC was used to corroborate the two binding
events between Shp2 and Grb2Y160E. Grb2Y160E (200 µM) was titrated into Shp2Δ69 (25 µM). Twelve 3 µl injections of Grb2Y160E were titrated into
Shp2Δ69. Top panel: baseline-corrected power versus time plot for the titration. Bottom panel: the integrated heats and the molar ratio of the Grb2Y160E to
Shp2Δ69.
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pErk1/2) through binding to Shp2 without the need for phos-
phorylation of the latter. Cell proliferation is a well-known
marker for MAPK signalling upregulation so we investigated
whether this was differentially affected by the presence of Grb2WT
or Grb2Y160E expression using MDA468 cells. In the absence of
extracellular stimulation, we observed that the expression of
Grb2Y160E enhanced the level of cellular proliferation compared
with wild type (Fig. 4e and Supplementary Data 4).
Discussion
Kinase and phosphatase activity have to be precisely controlled to
limit aberrant signal transduction in cells35,36. It has previously
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been demonstrated that Shp2 function is dependent on RTK
activity37–41, and is accompanied by phosphorylation of tyrosine
residues Y542 and Y580. This appears to facilitate a conforma-
tional change that abrogates an intramolecular interface between
the NSH2 and PTP domains of Shp2 and relieves the auto-
inhibited state26. Activated Shp2 can play a role in proliferative
signalling through the Erk1/2 pathway3,4,37.
In this work, we show that the upregulation of Shp2 can also be
accomplished in the absence of RTK activity, through the binding of
the monomeric adaptor protein Grb2 (mGrb2). Monomeric Grb2
will be present in cells in which the adaptor protein is expressed at
low concentrations (dimer-monomer equilibrium Kd= 0.8 µM29,30),
or as the result of phosphorylation on Y160 by constitutive, back-
ground RTK activity in the absence of ligand stimulation28. The SH2
and CSH3 domains of Grb2 form a bidentate interaction with the
NSH2 and PTP domains of Shp2, respectively. Interaction with Shp2
in this way results in an mGrb2-dependent conformational change
which opens the auto-inhibited state to facilitate phosphatase
activity.
The relevance of a mechanism for Shp2 upregulation in non-
stimulated cells is likely to be associated with the requirement of
cells to maintain homoeostatic and metabolic ‘house-keeping’
function in the absence of extracellular stimulation. We have
previously shown that similar functional activation of enzymes
and adaptors associated with RTK-mediated signalling pathways
occurs under basal conditions without the need for kinase
upregulation (e.g., Plcγ1;31 Shc33). This second tier of signal-
ling (tier 2 signalling), below the profound and defined effects of
full kinase activation resulting from extracellular stimulation, is
likely to be important in maintaining cell viability and in
responding to stress. Aberrancies in tier 2 signalling can also be
associated with cancer pathology31. This appears to be reflected
here where, through interaction with mGrb2, Shp2 can be
engaged in signalling in cancer cells without the need for muta-
ted, dysfunctional kinases. Therefore, in cells depleted for a given
RTK, as is found in triple-negative breast cancer (e.g., in MDA-
MB-468 cells, which do not express Her2; Fig. 4d), proliferative or
metastatic signalling could be driven by the uncontrolled impact
of monomeric Grb2-mediated Shp2 activation. The importance of
the interaction with Grb2 may also be emphasised by the
observation of two reported oncogenic Shp2 mutations in the
NSH2, which are localised at the identified Grb2-binding site,
namely T42A42 and N58K43. Change-of-function associated with
these mutations would potentially release regulatory control of
background tyrosine kinase-mediated signalling.
Non-stimulatory conditions portray many features of the early
phases of tumour development and progression as well as prevailing
in resistant cells treated with kinase inhibitors. Thus, the under-
standing of how signalling proteins behave and are controlled under
these conditions is the necessary foundation to develop more effi-
cient therapeutic strategies. It remains to be seen whether examples
of mGrb2-mediated activation of Shp2 are common regulators of
signalling in basal cells, and particularly whether aberrancies
resulting from environmental change-related stress can drive
tumorigenesis through perturbation of Grb2 concentration.
Methods
Cell culture. HEK293T cells were maintained in Dulbecco’s modified Eagle’s high
glucose medium supplemented with 10% (v/v) fetal bovine serum and 1% anti-
biotic/antimycotic (Lonza) in a humidified incubator with 10% CO2.
Reagents. Recombinant human epidermal growth factor (EGF) was purchased
from R&D Systems. Anti-Grb2 (sc-8034) were purchased from Santa Cruz Bio-
technology. Anti-GST (2624), anti-GFP (2956), anti-Tubulin (2146), anti-pEGFR
pY1173 (2244), anti-EGFR (4267), anti-Shp2 pY580 (3754), anti-pErk1/2 (4370)
and anti-Erk1/2 (9101) were from Cell Signalling Technology. Anti-RFP (A00682)
was purchased from Genscript. Anti-6xHis (631210) was purchased from Takara.
Anti-Shp2 antibodies were purchased from Santa Cruz Biotechnology, Cell Signal
Technology, Sigma or Abcam. Anti-Grb2 pY160 was synthesised from Genscript30.
Metafectin cell transfection reagents were purchased from Biontex.
Western blots. Cells were grown in 10-cm dishes, serum-starved overnight and
stimulated with 10 ng/ml EGF for 15 minutes. Cells were lysed with buffer con-
taining 50 mM Hepes, pH 7.5, 1% (vol/vol) igepal-C630, 1 mg/ml bacitracin, 1 mM
ethylenediaminetetraacetic acid, 10 mM NaF, 1 mM sodium orthovanadate, 10%
(vol/vol) glycerol, 50 mM NaCl, 1 mM phenylmethylsulfonyl fluoride and Protease
Inhibitor Cocktail Set III (EMD Millipore). The detergent-soluble fraction was used
for western blotting. Quantification of western blots was done using ImageJ
software.
Plasmids. For the pull-down assay, gene fragments encoding Grb2 and Shp2 (28) were
cloned into pGEX2T vector to construct GST-tagged Grb2 domains (GST-Grb2NSH3,
GST-Grb2SH2 and GST-Grb2CSH3) or Shp2 domains (GST-Shp2WT, GST-Shp2C459S,
GST-Shp22SH2, GST-Shp2PTP and GST-Shp2C69) using BamHI and NotI sites. For the
cellular FLIM study, Grb2 genes (Grb2WT or Grb2Y160E) were cloned in pECFP vector,
and Shp2 C-terminal tail truncation (Shp2Δ69) was cloned in pcDNA-RFP vector using
BamHI and NotI sites. For RFP-trap immunoprecipitation assay, Shp22SH2 and Shp2PTP
were cloned in pcDNA-RFP vector using BamHI and NotI sites. For cell-based strep-tag
pull-down experiments, Grb2 genes (Grb2WT or Grb2Y160E) were amplified with an
N-terminal strep-tag and cloned in a pcDNA6 vector using HindIII and PmeI sites. For
the in vitro FRET assay, Shp2 Δ69 was fused with an N-terminal BFP tag and a
C-terminal GFP tag and was cloned in a pET28b vector. Mutagenesis (GST-Shp22SH2
R32A, GST-Shp22SH2 R138A, GST-Shp22SH2 R32/138A and Grb2R86A/Y160E) was carried out
using Q5 site-directed mutagenesis kit (NEW England Biolabs) according to the
manufacturer’s protocol. To express recombinant proteins were in Escherichia coli for
in vitro phosphatase assay, biophysical assay, pull-down assay and NMR studies. Genes
of interest were amplified using standard PCR methods. Following designated restric-
tion enzyme digestions, fragments were ligated into pET28b (Shp2WT, Shp2Δ69,
Shp22SH2, Shp22SH2 R32/138A, Shp2NSH2, Shp2CSH2, Shp2PTP, Grb2WT, Grb2Y160E,
Grb2R86A/Y160E).
Protein expression and purification. Proteins were expressed in BL21 (DE3) cells.
In all, 20 ml of cells grown overnight were used to inoculate 1 litre of LB media
with antibiotic (50 µg/ml kanamycin for pET28b-backboned plasmids or 50 µg/ml
ampicillin for pGEX4T1-backboned plasmids). The culture was grown at 37°C with
Fig. 4 Grb2Y160E upregulates Shp2 activity in a phosphorylation-independent manner. a The effect of mGrb2 binding on Shp2 conformation was studied
using steady-state FRET. 0.1 µM of Shp2Δ69 was N-terminally tagged with a BFP and C-terminally tagged with a GFP. Upon Grb2Y160E titration, the emission
of both FRET donor (BFP) and acceptor (GFP) was recorded. b In vitro phosphatase assay using recombinant-unphosphorylated Shp2Δ69 (0.1 µM) and
Grb2 (WT or Y160E). Free phosphate generated from hydrolysis of the pY from the substrate peptide (ENDpYINASL) was measured by the absorbance of
a malachite green molybdate phosphate complex. The increasing concentration of Grb2Y160E gradually enhances Shp2 activity while the dimeric Grb2 has
no effect on Shp2 activity. The graph represents the results of three independent experiments. c In vitro phosphatase assay using both recombinant-
unphosphorylated (0.1 µM) and phosphorylated (0.1 µM) full-length Shp2 to compare the degree of enhanced phosphatase activity mediated by mGrb2
(10 µM) binding. This assay demonstrates that the mGrb2 binding-induced enhancement of Shp2 activity is comparable to the phosphorylated Shp2. The
graph represents the results from two independent experiments, each independent experiment contained three technical repeats. d Activation of Shp2 and
Erk1/2 in MDA-MD 468 cells in the absence of EGF ligand stimulation. The activation levels of both Shp2 and Erk1/2 in the absence (−) or presence (+) of
EGF ligand stimulation are analysed and shown as densitometric analysis. The blot represents three independent experiments. Inset: Grb2 is tyrosine
phosphorylated in MDA-MD-468 cells in the absence of EGF stimulation. e MTT cell proliferation assay of MDA-MD-468 cells expressing either Grb2WT
(blue) or Grb2Y160E (red). The graph represents the results from two independent experiments, each independent experiment contained 24 technical
repeats. Results are represented as mean ± SD. Statistics were determined using an unpaired Student’s t test.
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constant shaking (200 rpm) until the OD600= 0.7. At this point, the culture was
cooled down to 18°C and 0.5 mM of isopropyl β- d-1-thiogalactopyranoside was
added to induce protein expression for 12 h before harvesting. Harvested cells were
suspended in Talon buffer A (20 mM Tris, 150 mM NaCl and 1 mM β-ME, at pH
8.0) and lysed by sonication. Cell debris was removed by centrifugation (20,000
rpm at 4°C for 1 h). The soluble fraction was applied to an Akta Purifer System
for protein purification. Elution was performed using Talon buffer B (20 mM Tris,
150 mM NaCl, 200 mM imidazole and 1 mM β-ME at pH 8.0). Proteins were
concentrated to 2 ml and applied to a Superdex SD75 column using a HEPES
buffer at pH 7.5 (20 mM HEPES, 150 mM NaCl and 1 mM TCEP, at pH 7.5).
Pull-down/immunoprecipitation. Purified protein or total transfected HEK293T
cell lysate were prepared in 1 ml volume for pull-down or immunoprecipitation. In
all, 50 μl of 50% glutathione beads (Sigma), Strep-Tactin beads, MERCK or RFP-
Trap beads, Chromotek) were added and incubated for overnight. The beads were
spun down at 5000 rpm for 3 minutes, supernatant was removed and the beads
were washed with 1 ml lysis buffer. This washing procedure was repeated five times
in order to remove non-specific binding. After the last wash, 50 μl of 2× Laemmli
sample buffer were added, the samples were boiled and subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and western blot assay.
Fluorescence lifetime imaging microscopy. HEK293T cells were co-transfected
with cyan fluorescent protein- and red fluorescent protein-tagged Grb2 and Shp2,
respectively, (CFP-Grb2 and RFP-Shp2). After 24 h cells were seeded onto glass
coverslips and allowed to grow for a further 24 h, fixed by the addition of 4%
(w/vol) paraformaldehyde pH 8.0. Following 20 min incubation at room tem-
perature cells were washed 6–7 times with phosphate-buffered saline (PBS), pH 8.0.
Coverslips were mounted onto a slide with a mounting medium (0.1% p-pheny-
lenediamine and 75% glycerol in PBS at pH 7.5–8.0). FLIM images were captured
using a Leica SP5 II confocal microscope with an internal FLIM detector. CFP was
excited at 860 nm with titanium–sapphire pumped laser (Mai Tai BB, Spectral
Physics) with 710–920 nm tunability and 70 femtosecond pulse width. A Becker &
Hickl SPC830 data and image acquisition card was used for time-correlated single-
photon counting (TCSPC); electrical time resolution was 8 picoseconds with a pixel
resolution of 256 × 256. Data processing and analysis were performed using a B&H
SPC FLIM analysis software. The fluorescence decays were fitted to a single
exponential decay model.
Isothermal titration calorimetry. ITC experiments were carried out using a
MicroCal iTC200 instrument (Malvern), and data were analysed using
ORIGIN7 software. To avoid heats associated with protein dissociation, Grb2Y160E
was titrated into Shp2Δ69 at 25°C. The heat per injection was determined and
subtracted from the control (buffer into Shp2Δ69) binding data. Data were analysed
using a single independent site model using the Origin software.
Microscale thermophoresis. The Grb2 and Shp2 interactions were measured
using the Monolith NT.115 MST instrument from Nanotemper Technologies.
Proteins were fluorescently labelled with Atto 488 NHS ester (Sigma) according to
the manufacturer’s protocol. Labelling efficiency was determined to be 1:1 (protein
to dye) by measuring the absorbance at 280 nm and 488 nm. A solution of unla-
belled protein was serially diluted in the presence of 100 nM labelled protein. The
samples were loaded into capillaries (Nanotemper Technologies). Measurements
were performed at 25 °C in 20 mM HEPES buffer, pH 7.5, with 150 mM NaCl,
0.5 mM TCEP and 0.005% Tween 20, Data analyses were performed using
Nanotemper Analysis software, v.1.5.41 and plotted using OriginPro 9.1.
Biolayer interferometry. BLI experiments were performed using a FortéBio Octet
Red 384 using Anti-GST sensors. Assays were done in 384-well plates at 25°C.
Association was measured by dipping sensors into solutions of analyte protein for
120 seconds and was followed by moving sensors to wash buffer for 120 seconds to
monitor the dissociation process. Raw data show a rise in signal associated with
binding followed by a diminished signal after application of wash buffer.
In vitro phosphatase assay. In vitro Shp2 activity assays were carried out using
the Tyrosine Phosphatase Assay System (Promega) according to the manu-
facturer’s manual. In brief, recombinant Shp2Δ69 was mixed with the phospho-
peptide substrate in the presence or absence of different concentrations of Grb2
(Grb2WT or Grb2Y160E). The method is based on measuring the absorbent change
generated after the formation of a reaction mixture of molybdate:malachite green-
phosphate complex of the free phosphate. The reaction time was 15 minutes for all
experiments reported.
MTT cell proliferation assay. MDA468 proliferation assay was performed using
Vybrant® MTT Cell Proliferation Assay Kit (ThermoFisher) according to the
manufacturer’s protocol. In brief, cells were transfected and seeded in 96-well
plates. After overnight serum-starvation using phenol red-free medium, cells were
labelled with 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide (MTT)
for 4 hours at 3°C and dimethyl sulfoxide (DMSO) was used as the solubilizing
agent to dissolve the formazan. Absorbance was measured at 470 nm. The per-
centage of viable cells was determined by normalising absorbance of culture
medium treated with MTT and DMSO.
Nuclear magnetic resonance spectroscopy. Backbone resonances for the
1H, 15N, 13C labelled sample of Shp2NSH2 were assigned by recording a standard
Bruker or BEST TROSY version44 of 3D backbone resonance assignment spectra
(HNCA, HNCOCA, HNCACB, CACBCONH, HNCO and HNCACO) with NUS
sampling technique (25% fraction). The titration experiments of Grb2SH2 into
Shp2NSH2 were recorded using 15N HSQC pulse sequence from Bruker standard
library. For that, samples of 200 µM uniformly 15N-labelled Shp2NSH2 in 20 mM
HEPES, 150 mM NaCl, 0.5 mM TCEP. pH 7.5 and 10% (v/v) D2O with 1:1, 1:2,
1:3, 1:4, 1:5, 1:6 molar ratio of Shp2NSH2:Grb2SH2 were prepared. All measurements
were recorded at 25°C using a Brüker Avance III 750MHz and 950MHz spec-
trometers equipped with a Bruker TCI triple-resonance cryogenically coiled probes.
Data were processed with NMRPipe45 and analysed with CcpNmr Analysis soft-
ware package46. CSPs for individual residues were calculated from the chemical
shift for the backbone amide 1H (ΔωH) and 15N (ΔωN) using the following
equation: CSP ¼ p Δω2H þ 0:154Δω2N
  
47. For the assignment of residues in
the NSH2 domain of Shp2 coverage of non-proline residues was 81% complete.
The first nine N-terminal residues remain unassigned and there is a gap in
assignment of six and four residues at amino acid numbers 33–38 and 84–87,
respectively.
Statistics and reproducibility. All data were expressed as mean and standard
deviation. P values were determined by the Student’s unpaired t test (Figs. 1e and
2c were calculated using Student’s paired t test). The reproducibility was deter-
mined by using biological replicates and repeating the experiment two or three
times as described in the figure legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
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